GRI

GRI Bio, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website gribio.com
Employees(FY) 1
ISIN US3622AW3040

Performance

-12.63%

+7.98%

+60.87%

-74.83%

-97.89%

YTD

-97.99%

Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Advanced Technical Analysis

Technical Analysis of GRI 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 16 and the Technical Score at 28, both indicating weakness, while the Oscillators Score at 40 suggests a neutral stance. This combination implies a lack of strong bullish momentum, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of GRI

Stock Rank

Recent News & Updates

2024-12-05 19:35
GRI Bio to Participate in the Virtual Investor Closing Bell Series(Globenewswire)
2024-11-20 19:45
GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)(Globenewswire)
2024-11-14 03:20
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis(Globenewswire)
2024-10-23 20:30
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024(Globenewswire)
2024-10-21 05:35
GRI Bio Announces Exercise of Warrants(Globenewswire)
2024-10-15 20:45
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)(Globenewswire)
2024-10-06 20:30
GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis(Globenewswire)
2024-09-29 20:30
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions(Globenewswire)
2024-09-25 20:00
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia(Globenewswire)
2024-09-24 20:45
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment(Globenewswire)
2024-09-17 21:00
GRI Bio Participates in Virtual Investor KOL Connect Segment(Globenewswire)
2024-09-04 20:45
GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-09-03 20:45
GRI Bio to Present at the 2024 European Respiratory Congress(Globenewswire)
2024-08-13 20:05
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-07-14 21:05
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series(Globenewswire)
2024-07-10 21:20
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor What This Means Segment(Globenewswire)
2024-07-07 21:05
GRI Bio Regains Compliance with Nasdaq(Globenewswire)
2024-07-01 21:05
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine(Globenewswire)
2024-06-30 20:45
GRI Bio to Present at the 8th Annual IPF Summit(Globenewswire)
2024-06-28 04:05
GRI Bio Announces Closing of $4.0 Million Public Offering(Globenewswire)
2024-06-26 21:00
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators(Globenewswire)
2024-06-26 20:00
GRI Bio Announces Pricing of $4 Million Public Offering(Globenewswire)
2024-06-25 20:23
Why Is GRI Bio (GRI) Stock Down 29% Today?(Investorplace)
2024-06-25 19:41
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday(Investorplace)
2024-06-23 19:16
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-06-16 20:00
Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024(Accesswire)
2024-06-13 20:05
GRI Bio Announces Reverse Stock Split(Globenewswire)
2024-06-12 04:15
Connect Biopharma Announces New Leadership and Chair of the Board of Directors(Globenewswire)
2024-06-10 21:00
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference(Globenewswire)
2024-06-09 20:00
JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024(Accesswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.